about
Polymorphisms in SLCO1B3 and NR1I2 as genetic determinants of hematotoxicity of carboplatin and paclitaxel combination.Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumorsThymidylate synthase genotype-directed neoadjuvant chemoradiation for patients with rectal adenocarcinoma.Detection of the G>C SNP and rare mutations in the 28-bp repeat of TYMS using gel-based capillary electrophoresis.Genotyping of a family with a novel deleterious DPYD mutation supports the pretherapeutic screening of DPD deficiency with dihydrouracil/uracil ratio.Irreversible hepatotoxicity after administration of trabectedin to a pleiomorphic sarcoma patient with a rare ABCC2 polymorphism: a case report.UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice.Pharmacogenetics-based personalized therapy: Levels of evidence and recommendations from the French Network of Pharmacogenetics (RNPGx).Pharmacogenetics of anti-cancer drugs: State of the art and implementation - recommendations of the French National Network of Pharmacogenetics.Pilot study of neoadjuvant treatment with erlotinib in nonmetastatic head and neck squamous cell carcinoma.Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma.Population analysis of erlotinib in adults and children reveals pharmacokinetic characteristics as the main factor explaining tolerance particularities in children.Serum cystatin C is a better marker of topotecan clearance than serum creatinine.Pharmacokinetics of oxaliplatin during open versus laparoscopically assisted heated intraoperative intraperitoneal chemotherapy (HIPEC): an experimental study.Contribution of the MDRD equation and of cystatin C for renal function estimates in cancer patients.[Interest of cystatin C for individual dosing of anticancer drugs cleared by the kidneys].Inhibition of OCT2, MATE1 and MATE2-K as a possible mechanism of drug interaction between pazopanib and cisplatin.Estimation of unbound carboplatin clearance from total plasma concentrations as a means of facilitating therapeutic drug monitoringSevere toxicity to capecitabine due to a new variant at a donor splicing site in the dihydropyrimidine dehydrogenase gene[Importance of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer]Determination of unbound fraction of pazopanib in vitro and in cancer patients reveals albumin as the main binding siteLethal 5-fluorouracil toxicity in a colorectal patient with severe dihydropyrimidine dehydrogenase (DPD) deficiency[Interest of UGT1A1 genotyping within digestive cancers treatment by irinotecan]Reply to the letter addressed by Amr A. EL-Arabey "Dual function of OCT-2 and MATE1 in Cisplatin induced nephrotoxicity"Therapeutic drug monitoring and dose adaptation of cisplatin in a newborn with hepatoblastoma: a case reportFactors Affecting Tamoxifen Metabolism in Patients With Breast Cancer: Preliminary Results of the French PHACS StudyCetuximab pharmacokinetic/pharmacodynamics relationships in advanced head and neck carcinoma patients
P50
Q33425137-60E9C7E9-FA31-4D4A-BC0B-59D4011CFE4AQ34480582-BA2CF5E0-8410-497C-9B47-D37B23D99DF1Q34743494-B7C63C64-67C6-4D19-B093-8C59060DFC9CQ35083755-79580F72-FC0B-4E79-86BE-6521E48E4460Q35743233-5EE5B530-7347-4365-979E-2959589FBE25Q38136298-9707690C-8BA5-4D0A-B526-EF6EF956B2A3Q38393997-79210CC0-9C4A-4C7F-A637-E8C103E9FC2AQ38942177-CD6619F3-147F-4F59-A5B9-10FF264C9AEFQ39163254-422BBA5D-D5CB-4C3C-ABBB-377BCC907C25Q42522118-0F60F7C1-5DD0-4EB1-9CF0-3AEA115FABADQ45970694-F0A29DDE-DD99-41A1-9BFC-E52DF81D3AE6Q46041320-918E0EBE-054C-44AE-94ED-64F5E0F248E7Q46443641-15A79CBD-8133-4199-8518-E6DC98BC24EFQ46944790-CEA8E2DE-3793-4189-B637-8198EF837FB7Q51942834-D96DE831-85E3-4186-8737-031EF9E1E2CBQ52404220-CEA9F7F6-28D5-4299-AD32-1711DDC56063Q54194574-36780500-753F-42C5-B4EA-3D5A9C83F4F2Q57298235-3271AB6F-80CE-49B2-A24F-8D8E8A33DA5AQ57815793-BFF076C2-7009-443C-B0C8-D9DD899E9EE9Q84964539-5ED5363C-F5E4-4D5F-B51F-D22788A08DCCQ86706636-08313079-70B9-4200-A87F-4A7ECDAC6327Q86970507-2A0DEAA0-8143-40C4-85CF-5FDD8A186400Q88180940-8127909D-4DB2-4739-900F-5D7119159D3BQ88848243-36076882-E279-43B5-A927-00404D0DFFF2Q89161114-DA911326-1086-4AF5-9425-D63B9E047A5FQ91749095-A468FB7F-C339-48C3-8382-F952B4D652C7Q91961580-EC5BF2A3-455A-4729-8BB3-992167D9A278
P50
description
researcher ORCID ID = 0000-0001-9886-412X
@en
wetenschapper
@nl
name
Fabienne Thomas
@ast
Fabienne Thomas
@en
Fabienne Thomas
@es
Fabienne Thomas
@nl
type
label
Fabienne Thomas
@ast
Fabienne Thomas
@en
Fabienne Thomas
@es
Fabienne Thomas
@nl
prefLabel
Fabienne Thomas
@ast
Fabienne Thomas
@en
Fabienne Thomas
@es
Fabienne Thomas
@nl
P31
P496
0000-0001-9886-412X